Universe Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Universe Pharmaceuticals generated cash of $1,120,082, which is more than the previous year. Cash used in financing activities reached the amount of -$1,390,646 last year. Net change in cash is therefore -$426,211.
Cash Flow
| 2018 | 4.45M | -145.09K | -4.91M |
|---|---|---|---|
| 2019 | 13.20M | -86.03K | -16.00M |
| 2020 | 6.11M | -51.79K | 470.13K |
| 2021 | -2.05M | -27.05M | 26.58M |
| 2022 | -1.31M | -3.90M | 3.31M |
| 2023 | 1.12M | -44.16K | -1.39M |
UPC Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 5.71M | 8.07M | 10.05M | 3.17M | 6.19M | 6.98M |
Operating activities | ||||||
Net income | -6.16M | -8.73M | 11.31M | 7.55M | 7.55M | 7.60M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 508.78K | 533.94K | 446.87K | 410.07K | 418.43K | 452.73K |
Stock-based compensation expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred income tax benefit | 0 | 0 | 0 | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 4.71M | -1.54M | -3.86M | -4.10M | 665.48K | -2.81M |
Inventories | -1.18M | 16.58K | -451.63K | 888.60K | 5.58M | -327.25K |
Accounts payable | 1.64M | -1.89M | 2.45M | 639.42K | -924.44K | 265.17K |
Cash generated by operating activities | 1.12M | -1.31M | -2.05M | 6.11M | 13.20M | 4.45M |
Investing activities | ||||||
Purchases Of Investments | 0 | 0 | -15.33M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -44.16K | -93.70K | -13.53M | -51.79K | -86.32K | -145.09K |
Acquisitions Net | 0 | -3.81M | 26.61M | 0 | 291 | 0 |
Cash generated by investing activities | -44.16K | -3.90M | -27.05M | -51.79K | -86.03K | -145.09K |
Financing activities | ||||||
Common Stock Issued | 0 | 0 | 28.75M | 0 | 0 | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | -16.00M | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -1.39M | 0 | -3.67M | -1.42M | 1.14K | -5.50M |
Cash used in financing activities | -1.39M | 3.31M | 26.58M | 470.13K | -16.00M | -4.91M |
Net Change In Cash | -426.21K | -2.36M | -1.98M | 6.88M | -3.01M | -793.23K |
Cash at end of period | 5.28M | 5.71M | 8.07M | 10.05M | 3.17M | 6.19M |
| Data source | Data source | Data source |